Optimizing absorption, distribution, metabolism, and excretion (ADME) is an important part of small molecule drug discovery. Many machine learning models have been built to predict ADME properties to facilitate this optimization process, but explaining model predictions is challenging. We propose a new graph neural network architecture with built-in meaningful per-atom attributions. Our model MolLedger outputs predictions that are the sum of per-atom scores. MolLedger's additive framework obtains exact interpretability at no cost to performance because the global context vector gives the additive head enough context to produce good per-atom scores. Furthermore, MolLedger produces attributions that are more faithful to chemical properties than other interpretability methods because the auxiliary loss in MolLedger anchors the atom scores to chemical properties. Our case studies comparing interpretations from multiple methods on molecular pairs reveal that MolLedger is much better at producing sensible explanations for predicted property changes.
Magnus H. Strømme, Alex G. C. de Sá, David B. Aschercs.LG
Molecular toxicity prediction is increasingly used to prioritise compounds before experimental testing, but conventional benchmark performance can overstate practical utility when structurally related molecules occur across training and test folds. We introduce ToxLens, a reproducible multi-task graph-learning framework for 11 toxicity endpoints spanning Ames mutagenicity, acute oral toxicity, hERG inhibition, and Tox21 nuclear-receptor and stress-response assays. The workflow combines conservative chemical curation, sphere-exclusion filtering, a leakage-aware UMAP-HDBSCAN split, parallel graph and global-feature encoders joined by late concatenation, temperature-scaled Monte Carlo dropout with conformal-style prediction sets, applicability-domain analysis, and SHAP-guided toxicophore discovery with occlusion controls. On the leakage-controlled test fold, a five-seed soft-voting ensemble achieved a Matthews correlation coefficient score of 0.44, an area under the receiver operating characteristic curve score of 0.83, and an area under the precision-recall curve score of 0.58. It exceeded four ECFP4-based shallow baselines on all 11 endpoints under the same split and validation-based threshold-selection protocol. Controlled ablations showed that the global pathway was important, whereas late concatenation outperformed the tested gated and feature-wise linear modulation fusion variants. Conformal-style prediction sets revealed substantial endpoint-specific variation in set efficiency, and discrimination and calibration improved with similarity to the training domain. Retraining on fixed published Tox21 Challenge and TDA folds produced competitive, but not uniformly state-of-the-art, performance. SHAP-guided occlusion and consensus subgraph mining yielded model-derived structural hypotheses, 44 of which contained at least one occurrence that passed the predefined counterfactual criteria.
Predicting the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of small molecules remains a major challenge in drug discovery. Here, we present MEGA-CL, a foundation graph neural network framework for universal molecular ADMET prediction. MEGA-CL integrates self-supervised contrastive learning with a multi-head external attention mechanism and an enhanced message-passing architecture, enabling simultaneous modeling of local chemical substructures and global inter-graph relationships while mitigating over-smoothing effects commonly observed in deep graph networks. Across 13 benchmark datasets and 21 downstream ADMET tasks, MEGA-CL consistently outperforms state-of-the-art baseline models. In particular, the framework demonstrates robust performance on challenging regression tasks, including clearance (CL) and steady-state volume of distribution (VDss), while maintaining strong generalization ability in independent external validation. Clinically relevant predictive accuracy was achieved, with more than 75% of predictions falling within a 3-fold error range. In an external evaluation on 18 novel compounds derived from recently approved FDA drugs, over 50% of human liver microsome clearance (HLMC) predictions were within a 2-fold error range. To further assess its practical applicability, MEGA-CL was prospectively evaluated on three preclinical drug candidates using in vitro hepatic microsomal metabolism assays and CYP450 inhibition assays guided by model predictions. The predicted HLMC values for all candidates were within 2.5-fold of the experimentally measured values, and 73.3% of CYP450 inhibition endpoints (11/15) were correctly classified. These results demonstrate the potential of MEGA-CL as a generalizable framework for accelerating in silico ADMET evaluation and early-stage drug candidate optimization.
Molecular property prediction from structure often uses a single representative conformation, even though many molecules exist as conformational ensembles in solution. We introduce EnsembleEGNN, a molecular ensemble foundation model that encodes an ensemble by first encoding each conformer with shared Equivariant Graph Neural Network (EGNN) layers, then pooling the resulting conformer representations with a Set Attention Block. We pretrain the model on CREMP, a cyclic peptide ensemble dataset, using a multi-task self-supervised objective combining masked token recovery, noisy-coordinate reconstruction, and pairwise distance reconstruction. On the CREMP-CycPeptMPDB dataset, training EnsembleEGNN from scratch fails entirely ($R^2=0.005$). However, the pretrained model reaches $R^2=0.477$ and Pearson $r=0.699$, outperforming the sequence-only BERT baseline ($R^2=0.439$, Pearson $r=0.667$). When EnsembleEGNN is co-trained end-to-end with the BERT sequence encoder, the hybrid model improves further to $R^2=0.538$ and Pearson $r=0.737$. These results demonstrate that encoding conformational ensembles into a single thermodynamically informed embedding improves cyclic-peptide property prediction.
Hexiao Ding, Hongzhao Chen, Jing Lan +12cs.LG cs.AI
Accurate prediction of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) is important for drug discovery. Most predictors use undirected molecular graphs and pairwise edges. This choice misses asymmetric interactions, nonreversible dynamics, and motif level effects from functional groups and ring systems. We propose ChemHyperMag for multitask ADMET prediction under missing labels. ChemHyperMag builds a functional group hypergraph from rings, BRICS fragments, Bemis-Murcko scaffolds, and bonds. It also defines a potential driven nonreversible flow guided by electronegativity and Gasteiger partial charges. The resulting circulation is encoded by a Hermitian magnetic Laplacian and processed with a magnetic Chebyshev encoder. We perturb magnetic phases to form stochastic views and train with an InfoNCE objective. Experiments on multiple ADMET benchmarks show improvements over recent methods with fewer labeled samples and no conformers. ChemHyperMag is scalable and provides interpretable directional signals through its magnetic phases.
Jiacheng Zheng, Chang Guo, Zixuan Wang +2cs.LG q-bio.QM
Molecular property models are commonly evaluated by holding out Bemis-Murcko scaffolds, yet a scaffold identifier is only one notion of chemical unfamiliarity. We introduce a label-free structural-frontier split that reserves the sparsest and most physicochemically remote scaffold groups, and evaluate it on six public experimental or curated ADMET tasks. Against a 70/10/20 scaffold control with identical acyclic grouping, the frontier inflates equally weighted primary error with a taskwise median of 87.0% and a skew-sensitive mean of 130.3% (descriptive task/seed bootstrap interval, 52.1-246.0%). The mean falls to 75.9% once BBB is removed; that endpoint is the one whose score ranking inverts at the frontier. A message-passing graph-network control still shows a large gap (mean 82.8% over four tasks) and does not invert, so a low-capacity head does not explain the effect. We also test Multi-View Frontier Risk Extrapolation (MV-FREX), a count-adjusted tail-risk penalty over four molecular views, and treat it as a falsifiable probe. It changes normalized frontier error by only 0.16% relative to empirical risk minimization for the perceptron head (interval, -0.43-0.84%) and by -1.9% for the graph network; three fixed robust-penalty controls are likewise inconclusive. Against the published Lo-Hi and DataSAIL splitters, the frontier inflates error more on average, though no split is uniformly hardest. An audit of 31,561 marine natural products further shows that OOD status and agreement with legacy ADMET predictions depend on the molecular view, endpoint, and teacher coverage. Split construction and label provenance are important evaluation constraints in their own right, and the tested training penalties do not resolve the frontier failures we observe.
Yingxu Wang, Kunyu Zhang, Nan Yin +2cs.LG q-bio.QM
Motivation: Noisy labels are a common challenge in molecular property prediction because molecular annotations are often obtained from assays, curated databases, or weak annotation pipelines rather than directly observed clean biological states. Treating recorded labels as reliable supervision can cause models to memorize corrupted observations and learn misleading molecular evidence. In multimodal molecular representation learning, this issue can be amplified by graph-text fusion or alignment, which may propagate label-induced errors across modalities. Results: We propose MOLAR, a noise-aware framework for learning multimodal molecular representations from noisy labels. MOLAR separates latent clean-property inference from recorded-label observation: graph and text views contribute residual evidence to a clean-property distribution, and a categorical label-observation channel maps this distribution to recorded labels for training. This formulation derives posterior label reliability and modality-specific molecular evidence from the model. Experiments on naturally noisy molecular benchmarks and controlled label-flipping benchmarks show that MOLAR consistently outperforms representative baselines. Visualization analyses further show that MOLAR provides interpretable reliability and modality-evidence diagnostics.
Fundamental investigations into how different molecular encoding methods affect molecular property prediction remain relatively limited. In this study, we extensively examined the optimal molecular encoding methods for molecular properties prediction using two prevalent structure designs: a classical neural network model (MLP) and a Transformer encoder-based model (MLP+TL). For molecular encoding methods, we investigated several types of fingerprints, including traditional topological fingerprints, substructure-based fingerprints, and string-based representations. These two models were trained on seven well-known molecular datasets to evaluate different input molecular encoding methods based on evaluation metrics. On several biologically relevant classification tasks, including toxicity, mutagenicity, and side-effect prediction, our models consistently achieved average AUC values above 0.9. Rather than relying on external post-hoc explanation methods such as the local interpretable model-agnostic explanation (LIME) or the Deep SHapley Additive exPlanations (SHAP), we leveraged the model's intrinsic attention weights as an internal interpretability signal for identifying potentially important feature. The MLP+TL model using MACCS and PubChem as input can capture chemically interpretable groups that determined the major blood-brain barrier (BBB) permeability and mutagenicity in Salmonella typhimurium. In particular, a comparison between Morphine and Heroin highlighted the role of hydroxyl-related substructures in BBB permeability prediction, which was consistently reflected in the attention weights. Overall, our findings provide practical guidance for selecting effective molecular encoding methods and contribute to the development of interpretable molecular informatics approaches for drug discovery.
The rapid growth of molecular foundation models and general-purpose large language models has encouraged a scale-centric view of artificial intelligence in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models and task-specific graph neural networks (GNNs). We test this assumption on 22 molecular property and activity endpoints, including public ADMET and Tox21 benchmarks and two internal anti-infective activity datasets. Across 167,056 held-out task--molecule evaluations under structure-similarity-separated five-fold cross-validation (37,756 ADMET, 77,946 Tox21, 49,266 anti-TB and 2,088 antimalaria), classical machine-learning (ML) models such as RF(ECFP4) and ExtraTrees(RDKit descriptors) win ten primary-metric tasks, GNNs such as GIN and Ligandformer win nine, and pretrained molecular sequence models such as MoLFormer and ChemBERTa2 win three. Rule-based SAR reasoning baselines, represented by GPT5.5-SAR and Opus4.7-SAR, do not win under the prespecified primary metrics, although train-fold-derived SAR knowledge provides measurable but uneven gains for SAR reasoning and interpretation. These results indicate that compact, specialized models remain highly effective for molecular property and activity prediction. The performance differences among classical ML, GNN and pretrained sequence models are often modest and endpoint-dependent, whereas larger or more general models do not provide a universal predictive advantage. Large models may still add value for zero-shot reasoning, SAR interpretation and hypothesis generation, but the results suggest that predictive performance depends on the alignment among molecular representation, inductive bias, data regime, endpoint biology and validation protocol.